US2388261A - Riboflavin solution - Google Patents
Riboflavin solution Download PDFInfo
- Publication number
- US2388261A US2388261A US416757A US41675741A US2388261A US 2388261 A US2388261 A US 2388261A US 416757 A US416757 A US 416757A US 41675741 A US41675741 A US 41675741A US 2388261 A US2388261 A US 2388261A
- Authority
- US
- United States
- Prior art keywords
- riboflavin
- solution
- therapeutic
- boric acid
- heating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title description 92
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 title description 46
- 229960002477 riboflavin Drugs 0.000 title description 46
- 239000002151 riboflavin Substances 0.000 title description 46
- 235000019192 riboflavin Nutrition 0.000 title description 46
- 239000000243 solution Substances 0.000 description 40
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 16
- 239000004327 boric acid Substances 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 150000001639 boron compounds Chemical class 0.000 description 10
- 239000002253 acid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000003287 riboflavins Chemical class 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010047612 Vitamin B2 deficiency Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000007590 ariboflavinosis Diseases 0.000 description 2
- 150000001638 boron Chemical class 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 208000004223 riboflavin deficiency Diseases 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010008418 Cheilosis Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal borates Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229910052810 boron oxide Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- JKWMSGQKBLHBQQ-UHFFFAOYSA-N diboron trioxide Chemical compound O=BOB=O JKWMSGQKBLHBQQ-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- MOWNZPNSYMGTMD-UHFFFAOYSA-N oxidoboron Chemical class O=[B] MOWNZPNSYMGTMD-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
Definitions
- the present invention relates to improved therapeutic agents and more particularly to stabilized and solubilized riboflavin complexes.
- Riboflavin deficiency is very widespread and in certain parts of the United States it is considered to be the most widespread single vitamin deficiency, particularly among children. Clinical symptoms of riboflavin deficiency include keratitis, cheilosis, mydriasis, photophobia, lassitude and anorexia.
- Riboflavin is only very slightly soluble in water and for this reason has not been found satisfactory for administration by hypodermic injection.
- the natural solubility of riboflavin in pure water, for example, is only about 0.012 per cent.
- Hypodermic administration or a good therapeutic dose in this form necessitates an injection of a very large volume of liquid.
- the dministration of mg. of riboflavin. for example, requires an injection of about 80 cc. of solution.
- One of the principal objects of the present invention is to provide a solubilized riboflavin composition adaptable for hypodermic administration.
- Another object of the present invention is to provide a stabilized riboflavin composition substantially free from deterioration.
- a further object of the present invention is to provide an improved stabilized and solubilized riboflavin composition characterized by high therapeutic value.
- boron compounds such as the acids and salts may be combined with riboflavin to form the desired complexes.
- boron compounds include: boric acid, boric anhydride, boron oxides, peroxides, etc, and salts including the alkali metal borates, sodium perborates, etc. The following examples will serve to illustrate the present invention.
- Example I About .03-0.1 percent pure crystalline riboflavin is suspended in water and about 0.1-2.0 per cent pure crystalline boric acid added. The percentages used are dependent on the concentrations desiredthe optimum amounts being ascertainable by preliminary experiment.- The riboflavinboric acid mixture is then heated at about 100 C. until the riboflavin goes into solution and the desired stable boron complex is formed. An example of a heating period is 4 hours at 80-90 C.the optimum times and temperature varying with the concentrations of riboflavin and boric acid employed.
- the pH may be adjusted to pH 3 to 7 by addition of an alkalinizer such as trior di-sodium phosphate.
- an alkalinizer such as trior di-sodium phosphate.
- a pH range of 4-6.6 is preferred.
- the riboflavin may be solubilized in the presence of other therapeutic agents, such as vitamin C or in B-complex factor solutions with thiamin, nicotinic acid, nicotinamide, pyridoxine, calcium pantothenate, choline, inositol, p-amino benzoic acid or any combination of the same, or in combination with amino acids.
- other therapeutic agents such as vitamin C or in B-complex factor solutions with thiamin, nicotinic acid, nicotinamide, pyridoxine, calcium pantothenate, choline, inositol, p-amino benzoic acid or any combination of the same, or in combination with amino acids.
- Example II About 1 part of riboflavin and 25 parts of borax are ground together and dissolved in 1000 parts of water. When solution is complete about 7.1 parts of concentrated hydrochloric acid are added to produce a pH of about 6.3-6.6. The resulting solution is next heated for about 2 hours at -90" C. and then cooled to room temperature.
- riboflavin and other compounds such as the various vitamins, amino-acids, or other physiologically valuable materials, such compounds may be added after the formation of the riboflavin-boron complex.
- the pH is adjusted to 3-7, and preferably 4-6.6. If an acid boron compound is used the pH may be raised by addition of an alkalinizer such as in Example I, while if an alkaline boron compound is used the pH may be lowered by addition of an acidic agent such as in Example II.
- an acid pH is preferred (e. g. 6.6-4) although stability does not decrease appreciably until the pH is alkaline, i. e. above pH '1 the neutral point.
- the boron complexes oi the present invention are soluble in water, e. g. at least 10 mg. oil riboflavin per 10 cc. solution, and form stable isotonic solutions adaptable for hypodermic administration. Tests have shown the solutions to retain their therapeutic potency and to be tree from deterioration and precipitate formation under varying conditions, e. g. at to 40 C. for several months. Although particularly adaptable for hypodermic use the riboflavin complexes are also satisfactory for oral administration.
- the method oi preparing a stable aqueous therapeutic solution containing not less than 0.03% of riboflavin and suitable for hypodermic administration, which comprises: P p ring a water solution containing from 0.1% to 2.0% of boric acid in solution, and from 0.03% to 0.10% of riboflavin; adjusting the pH 01' the solution to from 3.0 to 6.6; heating the solution until the CERTIFICATE OF Patent No. 2,588,261.
- riboflavin dissolves; and thereafter continuing the heating at temperatures above about C. for a period of time of about two to four hours, to secure a liquid product from which material will not crystallize out even after standing for months or years.
- the method 01 preparing a stable aqueous therapeutic solution containing not less than 0.03% o! riboflavin and suitable for hypodermic administration, which comprises: preparing a water solution having a pH not exceeding 7.0 and containing from 0.1% to 2.0% boric acid and from 0.03% to 0.10% o! riboflavin; heating the solution until the riboflavin dissolves; and thereafter continuing the heating at temperatures above about 80 C. until samples of the product show no precipitation on prolonged standing.
- a stable aqueous therapeutic solution containing from 0.1% to 2.0% of boric acid and more than 0.03% of riboflavin, said solution having a pH i'rom 4.0 to 6.6; the riboflavin and boric acid being in that state of combination resulting from prolonged heating for about two hours above 80 C.; said solution remaining stable indefinitely at room temperatures, without the precipitation of the therapeutic in crystalline form, and without deleterious decomposition of the therapeutic.
- the method of preparing a stable aqueous therapeutic solution containing not less than 0.33% of riboflavin and suitable for hypodermic administration which comprises: preparing a water solution having a pH not exceeding 7 and containing the negative radical of boric acid up to an amount corresponding to from 0.1% to 2.0% of boric acid, together with from 0.03% to 0.1% of riboflavin; heating the solution until the riboflavin dissolves; and thereafter continuing the heating at temperatures above about 00 C. until samples of the product show no precipitation on prolonged standing.
- the boron complexes oi the present invention are soluble in water, e. g. at least 10 mg. oil riboflavin per 10 cc. solution, and form stable isotonic solutions adaptable for hypodermic administration. Tests have shown the solutions to retain their therapeutic potency and to be tree from deterioration and precipitate formation under varying conditions, e. g. at to 40 C. for several months. Although particularly adaptable for hypodermic use the riboflavin complexes are also satisfactory for oral administration.
- the method oi preparing a stable aqueous therapeutic solution containing not less than 0.03% of riboflavin and suitable for hypodermic administration, which comprises: P p ring a water solution containing from 0.1% to 2.0% of boric acid in solution, and from 0.03% to 0.10% of riboflavin; adjusting the pH 01' the solution to from 3.0 to 6.6; heating the solution until the CERTIFICATE OF Patent No. 2,588,261.
- riboflavin dissolves; and thereafter continuing the heating at temperatures above about C. for a period of time of about two to four hours, to secure a liquid product from which material will not crystallize out even after standing for months or years.
- the method 01 preparing a stable aqueous therapeutic solution containing not less than 0.03% o! riboflavin and suitable for hypodermic administration, which comprises: preparing a water solution having a pH not exceeding 7.0 and containing from 0.1% to 2.0% boric acid and from 0.03% to 0.10% o! riboflavin; heating the solution until the riboflavin dissolves; and thereafter continuing the heating at temperatures above about 80 C. until samples of the product show no precipitation on prolonged standing.
- a stable aqueous therapeutic solution containing from 0.1% to 2.0% of boric acid and more than 0.03% of riboflavin, said solution having a pH i'rom 4.0 to 6.6; the riboflavin and boric acid being in that state of combination resulting from prolonged heating for about two hours above 80 C.; said solution remaining stable indefinitely at room temperatures, without the precipitation of the therapeutic in crystalline form, and without deleterious decomposition of the therapeutic.
- the method of preparing a stable aqueous therapeutic solution containing not less than 0.33% of riboflavin and suitable for hypodermic administration which comprises: preparing a water solution having a pH not exceeding 7 and containing the negative radical of boric acid up to an amount corresponding to from 0.1% to 2.0% of boric acid, together with from 0.03% to 0.1% of riboflavin; heating the solution until the riboflavin dissolves; and thereafter continuing the heating at temperatures above about 00 C. until samples of the product show no precipitation on prolonged standing.
Description
Patented Nov. 6, 1945 RIBOFLAVIN SOLUTION Douglas V. Frost, Waukegan, Ill., assignor to Abbott Laboratories, a corporation of Illinois No Drawing. Application October 27, 1941,
Serial No. 416,757
4 Claims.
The present invention relates to improved therapeutic agents and more particularly to stabilized and solubilized riboflavin complexes.
Riboflavin deficiency is very widespread and in certain parts of the United States it is considered to be the most widespread single vitamin deficiency, particularly among children. Clinical symptoms of riboflavin deficiency include keratitis, cheilosis, mydriasis, photophobia, lassitude and anorexia.
Riboflavin is only very slightly soluble in water and for this reason has not been found satisfactory for administration by hypodermic injection. The natural solubility of riboflavin in pure water, for example, is only about 0.012 per cent. Hypodermic administration or a good therapeutic dose in this form necessitates an injection of a very large volume of liquid. The dministration of mg. of riboflavin. for example, requires an injection of about 80 cc. of solution.
The need for a form of riboflavin satisfactory for hypodermic administration has long been recognized by the medical art. Prior attempts, however, to solve the problem, have been unsuccessful. Some prior suggestions have been found unsatisfactory because the proposed riboflavin com position precipitated or deteriorated on standing, while other suggestions have been found unsatisfactory because efiorts to improve solubility had deleteriously affected the desired therapeutic properties of the riboflavin. As far as is known, up to the time or the discovery upon which the present invention is based, no satisfactory form of riboflavin was available for hypodermic administration.
One of the principal objects of the present invention is to provide a solubilized riboflavin composition adaptable for hypodermic administration.
Another object of the present invention is to provide a stabilized riboflavin composition substantially free from deterioration.
A further object of the present invention is to provide an improved stabilized and solubilized riboflavin composition characterized by high therapeutic value.
Other objects will be apparent as the description proceeds in detail hereinafter.
I have discovered that boron compounds such as the acids and salts may be combined with riboflavin to form the desired complexes. Examples of boron compounds include: boric acid, boric anhydride, boron oxides, peroxides, etc, and salts including the alkali metal borates, sodium perborates, etc. The following examples will serve to illustrate the present invention.
Example I About .03-0.1 percent pure crystalline riboflavin is suspended in water and about 0.1-2.0 per cent pure crystalline boric acid added. The percentages used are dependent on the concentrations desiredthe optimum amounts being ascertainable by preliminary experiment.- The riboflavinboric acid mixture is then heated at about 100 C. until the riboflavin goes into solution and the desired stable boron complex is formed. An example of a heating period is 4 hours at 80-90 C.the optimum times and temperature varying with the concentrations of riboflavin and boric acid employed.
If considerable boric acid is used the pH may be adjusted to pH 3 to 7 by addition of an alkalinizer such as trior di-sodium phosphate. Ordinarily for hypodermic administration a pH range of 4-6.6 is preferred.
The riboflavin may be solubilized in the presence of other therapeutic agents, such as vitamin C or in B-complex factor solutions with thiamin, nicotinic acid, nicotinamide, pyridoxine, calcium pantothenate, choline, inositol, p-amino benzoic acid or any combination of the same, or in combination with amino acids.
Example II About 1 part of riboflavin and 25 parts of borax are ground together and dissolved in 1000 parts of water. When solution is complete about 7.1 parts of concentrated hydrochloric acid are added to produce a pH of about 6.3-6.6. The resulting solution is next heated for about 2 hours at -90" C. and then cooled to room temperature.
If solutions are desired comprising riboflavin and other compounds such as the various vitamins, amino-acids, or other physiologically valuable materials, such compounds may be added after the formation of the riboflavin-boron complex.
In the compositions of the present invention, as will be noted by the above examples, the pH is adjusted to 3-7, and preferably 4-6.6. If an acid boron compound is used the pH may be raised by addition of an alkalinizer such as in Example I, while if an alkaline boron compound is used the pH may be lowered by addition of an acidic agent such as in Example II. The reason for maintaining the compositions within the specified pH range is stability. I have discovered, for example. t at riboflavin solutions lack the desired stability it maintained at pH values above 7. Ordinarily an acid pH is preferred (e. g. 6.6-4) although stability does not decrease appreciably until the pH is alkaline, i. e. above pH '1 the neutral point.
The boron complexes oi the present invention are soluble in water, e. g. at least 10 mg. oil riboflavin per 10 cc. solution, and form stable isotonic solutions adaptable for hypodermic administration. Tests have shown the solutions to retain their therapeutic potency and to be tree from deterioration and precipitate formation under varying conditions, e. g. at to 40 C. for several months. Although particularly adaptable for hypodermic use the riboflavin complexes are also satisfactory for oral administration.
The efiect of the boron compounds in solubilizing riboflavin is not clearly understood at present. Investigations, however, indicate that a relatively loose complex is formed and tests have shown the same to be chemically and physiologically stable when maintained within the specified pH range.
While various boron compounds, such as the oxides, may be substituted for the acid 0! Example I or other salts for the sodium tetraborate of Example 11, it will be understood that the boron compounds employed should be substantiall nontoxic. It will also be understood that the present invention is not limited to the above illustrative examples. All modifications oi the presout invention are intended to be covered by the following claims.
I claim:
1. The method oi preparing a stable aqueous therapeutic solution containing not less than 0.03% of riboflavin and suitable for hypodermic administration, which comprises: P p ring a water solution containing from 0.1% to 2.0% of boric acid in solution, and from 0.03% to 0.10% of riboflavin; adjusting the pH 01' the solution to from 3.0 to 6.6; heating the solution until the CERTIFICATE OF Patent No. 2,588,261.
riboflavin dissolves; and thereafter continuing the heating at temperatures above about C. for a period of time of about two to four hours, to secure a liquid product from which material will not crystallize out even after standing for months or years.
2. The method 01 preparing a stable aqueous therapeutic solution containing not less than 0.03% o! riboflavin and suitable for hypodermic administration, which comprises: preparing a water solution having a pH not exceeding 7.0 and containing from 0.1% to 2.0% boric acid and from 0.03% to 0.10% o! riboflavin; heating the solution until the riboflavin dissolves; and thereafter continuing the heating at temperatures above about 80 C. until samples of the product show no precipitation on prolonged standing.
3. A stable aqueous therapeutic solution containing from 0.1% to 2.0% of boric acid and more than 0.03% of riboflavin, said solution having a pH i'rom 4.0 to 6.6; the riboflavin and boric acid being in that state of combination resulting from prolonged heating for about two hours above 80 C.; said solution remaining stable indefinitely at room temperatures, without the precipitation of the therapeutic in crystalline form, and without deleterious decomposition of the therapeutic.
4. The method of preparing a stable aqueous therapeutic solution containing not less than 0.33% of riboflavin and suitable for hypodermic administration which comprises: preparing a water solution having a pH not exceeding 7 and containing the negative radical of boric acid up to an amount corresponding to from 0.1% to 2.0% of boric acid, together with from 0.03% to 0.1% of riboflavin; heating the solution until the riboflavin dissolves; and thereafter continuing the heating at temperatures above about 00 C. until samples of the product show no precipitation on prolonged standing.
DOUGLAS V. FROST.
CORRECTION.
November 6, 1914.5.
Douoms v. FROST.
It is hereby cc of the above numbered patent requiring cor for "0.55%"
Letters Patent should be read with this correc conform to the record of the case in the Patent Signed and sealed this 26th day of February, A. D.
0nd column, line 50, claim i (Seal) rtified that error appears in the printed s pecification rection as follows: Page 2, sec-- read --0.05%--; and that the said tion therein that the same may Office.
Leslie Frazer First Assistant Commissioner of Patents.
stability it maintained at pH values above 7. Ordinarily an acid pH is preferred (e. g. 6.6-4) although stability does not decrease appreciably until the pH is alkaline, i. e. above pH '1 the neutral point.
The boron complexes oi the present invention are soluble in water, e. g. at least 10 mg. oil riboflavin per 10 cc. solution, and form stable isotonic solutions adaptable for hypodermic administration. Tests have shown the solutions to retain their therapeutic potency and to be tree from deterioration and precipitate formation under varying conditions, e. g. at to 40 C. for several months. Although particularly adaptable for hypodermic use the riboflavin complexes are also satisfactory for oral administration.
The efiect of the boron compounds in solubilizing riboflavin is not clearly understood at present. Investigations, however, indicate that a relatively loose complex is formed and tests have shown the same to be chemically and physiologically stable when maintained within the specified pH range.
While various boron compounds, such as the oxides, may be substituted for the acid 0! Example I or other salts for the sodium tetraborate of Example 11, it will be understood that the boron compounds employed should be substantiall nontoxic. It will also be understood that the present invention is not limited to the above illustrative examples. All modifications oi the presout invention are intended to be covered by the following claims.
I claim:
1. The method oi preparing a stable aqueous therapeutic solution containing not less than 0.03% of riboflavin and suitable for hypodermic administration, which comprises: P p ring a water solution containing from 0.1% to 2.0% of boric acid in solution, and from 0.03% to 0.10% of riboflavin; adjusting the pH 01' the solution to from 3.0 to 6.6; heating the solution until the CERTIFICATE OF Patent No. 2,588,261.
riboflavin dissolves; and thereafter continuing the heating at temperatures above about C. for a period of time of about two to four hours, to secure a liquid product from which material will not crystallize out even after standing for months or years.
2. The method 01 preparing a stable aqueous therapeutic solution containing not less than 0.03% o! riboflavin and suitable for hypodermic administration, which comprises: preparing a water solution having a pH not exceeding 7.0 and containing from 0.1% to 2.0% boric acid and from 0.03% to 0.10% o! riboflavin; heating the solution until the riboflavin dissolves; and thereafter continuing the heating at temperatures above about 80 C. until samples of the product show no precipitation on prolonged standing.
3. A stable aqueous therapeutic solution containing from 0.1% to 2.0% of boric acid and more than 0.03% of riboflavin, said solution having a pH i'rom 4.0 to 6.6; the riboflavin and boric acid being in that state of combination resulting from prolonged heating for about two hours above 80 C.; said solution remaining stable indefinitely at room temperatures, without the precipitation of the therapeutic in crystalline form, and without deleterious decomposition of the therapeutic.
4. The method of preparing a stable aqueous therapeutic solution containing not less than 0.33% of riboflavin and suitable for hypodermic administration which comprises: preparing a water solution having a pH not exceeding 7 and containing the negative radical of boric acid up to an amount corresponding to from 0.1% to 2.0% of boric acid, together with from 0.03% to 0.1% of riboflavin; heating the solution until the riboflavin dissolves; and thereafter continuing the heating at temperatures above about 00 C. until samples of the product show no precipitation on prolonged standing.
DOUGLAS V. FROST.
CORRECTION.
November 6, 1914.5.
Douoms v. FROST.
It is hereby cc of the above numbered patent requiring cor for "0.55%"
Letters Patent should be read with this correc conform to the record of the case in the Patent Signed and sealed this 26th day of February, A. D.
0nd column, line 50, claim i (Seal) rtified that error appears in the printed s pecification rection as follows: Page 2, sec-- read --0.05%--; and that the said tion therein that the same may Office.
Leslie Frazer First Assistant Commissioner of Patents.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US416757A US2388261A (en) | 1941-10-27 | 1941-10-27 | Riboflavin solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US416757A US2388261A (en) | 1941-10-27 | 1941-10-27 | Riboflavin solution |
Publications (1)
Publication Number | Publication Date |
---|---|
US2388261A true US2388261A (en) | 1945-11-06 |
Family
ID=23651188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US416757A Expired - Lifetime US2388261A (en) | 1941-10-27 | 1941-10-27 | Riboflavin solution |
Country Status (1)
Country | Link |
---|---|
US (1) | US2388261A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2445208A (en) * | 1946-02-04 | 1948-07-13 | Wyeth Corp | Solutions of riboflavin |
US2459518A (en) * | 1946-06-27 | 1949-01-18 | Squibb & Sons Inc | Parenteral solutions of riboflavin and the like |
US2650894A (en) * | 1948-06-16 | 1953-09-01 | Mcneilab Inc | Riboflavin-monoborate and process for preparation thereof |
US4219545A (en) * | 1979-03-23 | 1980-08-26 | Collins Calvin E | Treatment of infectious keratoconjunctivitis in animals |
US4264601A (en) * | 1979-06-12 | 1981-04-28 | The Board Of Regents Of The University Of Oklahoma | Antihypertensive agents and their use in treatment of hypertension |
-
1941
- 1941-10-27 US US416757A patent/US2388261A/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2445208A (en) * | 1946-02-04 | 1948-07-13 | Wyeth Corp | Solutions of riboflavin |
US2459518A (en) * | 1946-06-27 | 1949-01-18 | Squibb & Sons Inc | Parenteral solutions of riboflavin and the like |
US2650894A (en) * | 1948-06-16 | 1953-09-01 | Mcneilab Inc | Riboflavin-monoborate and process for preparation thereof |
US4219545A (en) * | 1979-03-23 | 1980-08-26 | Collins Calvin E | Treatment of infectious keratoconjunctivitis in animals |
US4264601A (en) * | 1979-06-12 | 1981-04-28 | The Board Of Regents Of The University Of Oklahoma | Antihypertensive agents and their use in treatment of hypertension |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920008026A (en) | Isoquinolinone derivatives or nontoxic acid addition salts thereof or hydrates thereof, methods for preparing the same, and pharmaceutical compositions comprising the same | |
KR950703988A (en) | AQUEOUS PHARMACEUTICAL PREPARATIONS OF G-CSF WHTH A LONG SHELF LIFE | |
US4409233A (en) | Highly concentrated preparations of dopa compounds | |
SE8900828L (en) | ANTIVIRAL AND IMMUNSTIMULATING PHARMACEUTICAL COMPOSITIONS AND PROCEDURES FOR PREPARING THEM | |
US2388261A (en) | Riboflavin solution | |
IL27058A (en) | Novel salts of 5-(p-(2-pyridylsulphamyl)-phenylazo)-salicylic acid and method of producing same | |
US4780465A (en) | Aqueous solution containing a quinolone carboxylic acid | |
US2695860A (en) | Stabilized pteroyl solutions | |
US4185093A (en) | Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals | |
US2407412A (en) | Therapeutic solutions | |
JP3146218B2 (en) | Eye drops | |
ES8505922A1 (en) | Derivatives of 4-phenyl-4-oxo-buten-2-oic acid, their preparation, medicaments and compositions containing them. | |
US2939821A (en) | Stable solutions containing vitamin b12 | |
US4235900A (en) | Cephradine compositions | |
GB1053843A (en) | ||
JPS6333327A (en) | Stabilized phenylephrine liquid agent | |
US3767803A (en) | Stable aqueous pyritinol solutions | |
US2222952A (en) | Theophylline and caffeine solution | |
US2004891A (en) | Anaesthetic composition | |
US4327084A (en) | Aqueous solution for intravenous administration | |
US2498200A (en) | Stabilized thiamin | |
Lemaire et al. | The tris formulation of Fluorouracil is more cardiotoxic than the sodium-salt formulations | |
US3590039A (en) | N - (alpha,alpha,alpha,alpha',alpha',alpha' -hexafluoro - 3,5 - xylyl) anthranilic acid and salts thereof | |
US2850426A (en) | Anthelmintic piperazine-phosphoric acid compositions and method of combatting helminth infestations therewith | |
US2459518A (en) | Parenteral solutions of riboflavin and the like |